Pemetrexed maintenance therapy prolongs survival in nonsquamous NSCLC

Pemetrexed maintenance therapy offers a survival benefit over placebo and is well tolerated in patients with advanced nonsquamous non-small-cell lung cancer, final results of the PARAMOUNT trial show.
Source: MedWire News - Lung Cancer - Category: Cancer & Oncology Source Type: news